INS and type 1 diabetes mellitus: Moreover, the lower treatment satisfaction identified with insulin icodec in those with type 1 diabetes and the higher risk of hypoglycaemia, potentially resulting in safety issues, raise concerns and indicate the need for further investigation [34].